News Releases and Coverage
2024
March 1, 2024
PROTAC” modified dihydroquinolizinones (DHQs) that cause degradation of PAPD-5 and inhibition of hepatitis A virus and hepatitis B virus, in vitro - The authors are Blumberg Institute scientists and colleagues at the University of North Carolina.
Jan. 26, 2024
Jan. 5, 2024
Blumberg Institute presents 2023 Lam Excellence in Medicinal Chemistry Award
2023
Dec. 20, 2023
Hatch BioFund Announces New Partnership with Brandywine Realty Trust
Dec. 7, 2023
Pennsylvania couple to receive Hepatitis B Foundation’s Community Leadership Award
Oct. 19, 2023
Jim Greenwood, former Congressman, ex-CEO of the world’s top biotech industry association, honored at the Pennsylvania Biotechnology Center
Oct. 5, 2023
Blumberg Institute salutes Nobel Prize winners Katalin Kariko and Drew Weissman
Sept. 26, 2023
Capital Health Awarded NIH Funding for Bladder Cancer Detection Study
Sept. 19, 2023
Aug. 1, 2023
May 24, 2023
May 9, 2023
March 22, 2023
MERLIN BIOTECH reveals Novel Cancer Immunotherapy at Biotech Showcase ™ 2023
Jan. 17, 2023
Jan. 8, 2023
Pennsylvania Biotechnology Center in Doylestown is epicenter of startups, investment
2022
Dec. 22, 2022
Blumberg Institute presents 2022 Lam Excellence in Medicinal Chemistry Award
Nov. 29, 2022
The Blumberg Institute receives Angel Investment state funding thanks to Sen. Pat Browne
Nov. 4, 2022
MERLIN Biotech CEO to present at BioFuture Nov. 8
Oct. 28, 2022
Blumberg Institute launches certificate program in Pharmaceutical Research & Development
Oct. 13, 2022
Blumberg spinout wins pitch competition at Biotech Week Boston
Aug. 22, 2022
Buckingham man's liver cancer battle inspires new research lab. 'No other family should suffer'
Aug. 11, 2022
June 21, 2022
April 22, 2022
February 22, 2022
International society elects Blumberg Institute scientist as board secretary
February 2, 2022
Randall N. Hyer, MD, PhD, MPH, joins the Blumberg Institute faculty